ReviewDrugs2015
Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review.Canadian respiratory journal · 2025Pooled it
- Organotypic primary blood vessel models of clear cell renal cell carcinoma for single-patient clinical trials.Lab on a chip · 2020Trial
- Preparation, Characterization and Evaluation of Nintedanib Amorphous Solid Dispersions with Enhanced Oral Bioavailability.AAPS PharmSciTech · 2024Article
- Article
- Automated High-Throughput Live Cell Monitoring of Scratch Wound Closure.Biomedical engineering and computational biology · 2024Article
- Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis.Frontiers in pharmacology · 2022Review
- Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.Signal transduction and targeted therapy · 2021Review
- Review
- FGF/FGFR signaling in health and disease.Signal transduction and targeted therapy · 2020Review
- Nintedanib ameliorates animal model of dermatitis.Scientific reports · 2020Article
- Effect of nintedanib thermo-sensitive hydrogel on neovascularization in alkali burn rat model.International journal of ophthalmology · 2020Article
- Cross-dehydrogenative coupling reactions between arenes (C-H) and carboxylic acids (O-H): a straightforward and environmentally benign access toRSC advances · 2019Review
- Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy.Journal of hematology & oncology · 2019Review
- Gene Expression Changes Associated with Nintedanib Treatment in Idiopathic Pulmonary Fibrosis Fibroblasts: A Next-Generation Sequencing and Bioinformatics Study.Journal of clinical medicine · 2019Article
- Protective Effects of Nintedanib against Polyhexamethylene Guanidine Phosphate-Induced Lung Fibrosis in Mice.Molecules (Basel, Switzerland) · 2018Article
- The Management of Patients With Idiopathic Pulmonary Fibrosis.Frontiers in medicine · 2018Review
- An endostatin-derived peptide orally exerts anti-fibrotic activity in a murine pulmonary fibrosis model.International immunopharmacology · 2015Article
- Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives.BioMed research international · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nintedanib (Ofev(®)) inhibits receptor tyrosine kinases implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF). This article reviews the efficacy and tolerability of oral nintedanib in the treatment of IPF, as well as summarizing its pharmacological properties. In the randomized, double-blind, multinational, 12-month INPULSIS-1 and -2 trials in patients with IPF, nintedanib significantly reduced the decline in forced vital capacity versus placebo, indicating a slowing of disease progression. The time to first acute exacerbation was significantly increased with nintedanib in INPULSIS-2, but not in INPULSIS-1, and significantly less deterioration in health-related quality of life was seen with nintedanib in INPULSIS-2, but not in INPULSIS-1. Nintedanib had an acceptable tolerability profile in patients with IPF; gastrointestinal adverse events (diarrhoea, nausea, vomiting) were reported most commonly. In conclusion, nintedanib is an important new option for the treatment of IPF.
Indexed as
Identifiers
26063212What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.